Literature DB >> 25583234

Prognostic factors for the recurrence of myxoid liposarcoma: 20 cases with up to 8 years follow-up.

M Lemeur1, J-C Mattei2, P Souteyrand3, C Chagnaud3, G Curvale1, A Rochwerger1.   

Abstract

INTRODUCTION: Myxoid liposarcomas (MLS) are the second most common type of liposarcoma. Although some MRI findings are distinctively characteristics of MLS, the diagnosis can be tricky in tumors with a large portion of round cells (RC). Known predictors of an unfavorable outcome include age, tumor size, high RC content and positive resection margins. The goal of this retrospective study was to define prognostic factors for recurrence, with special emphasis on the percentage of RCs and medical care provided in a non-specialized center. PATIENTS AND METHODS: Twenty patients (11 women, 9 men) with a mean age of 44.3 years (18-73) were reviewed after a mean of 55.9 months. Six of these patients had been operated at a non-specialized center. The diagnostic MRI was read by a specialized radiologist and the resection procedures performed by two specialized surgeons. Tumors were labeled as either "pure myxoid liposarcoma" or "myxoid/round-cell liposarcoma". The local recurrence-free survival rate and mortality rate were calculated.
RESULTS: Fifteen patients had undergone an MRI during the initial assessment. The typical MRI findings of MLS were present in four of them. The MRI suggested a non-specific lesion in the other 11 patients. After correlation with pathology findings, these tumors contained more than 5% round cells. The fourteen patients treated at our facility had undergone a biopsy, while none of the ones treated outside did. Five patients had R0 resection margins and 15 had R1 margins. Prognostic factors for recurrence consisted of age, tumor size >10 cm, R1 resection margins, FNCLCC grade 2+R1 margins, medical care at a non-specialized center, and >5% round cells. There were eight local recurrences and three metastases (15%). Two patients died (90% overall survival rate). DISCUSSION: The risk of local recurrence was 3.86 times greater in this study when the tumor contained more than 5% RCs, which is consistent with published data. The MLS diagnosis was made only four times based on the initial MRI because misleading nature of high RC tumors. R1 resection margins are a risk factor for local recurrence. However, cases with R1 margins have a recurrence rate that is similar to R0 cases when the surgery is performed at a specialized cancer center. Treatment of MLS in a non-specialized center is a key negative prognostic factor. The reported rate of metastasis varies. Atypical extrapulmonary localizations are common, and often multifocal. MRI has been shown to be superior at detecting secondary lesions and some have suggested that a full-body MRI should be performed.
CONCLUSION: Prognostic factors for the recurrence of myxoid liposarcomas have been identified. MRI analysis is not definitive and must be supplemented by a biopsy.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Imaging; Myxoid liposarcoma; Prognostic factors; Recurrence; Round-cell percentage; Specialized center

Mesh:

Year:  2015        PMID: 25583234     DOI: 10.1016/j.otsr.2014.09.024

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  15 in total

1.  Early detection of metastases using whole-body MRI for initial staging and routine follow-up of myxoid liposarcoma.

Authors:  Natalia Gorelik; Santhosh Mauvva Venkatesh Reddy; Robert E Turcotte; Krista Goulding; Sungmi Jung; Thierry Alcindor; Thomas I Powell
Journal:  Skeletal Radiol       Date:  2017-12-23       Impact factor: 2.199

2.  Malignant intestinal obstruction during twin pregnancy: surgical resection of a myxoid liposarcoma without induction of labour.

Authors:  Christoph Paasch; Annette Isbruch; Martin W Strik; Robert Siegel
Journal:  BMJ Case Rep       Date:  2019-07-08

3.  Primary High-Grade Myxoid Liposarcoma of the Extremities: Prognostic Factors and Metastatic Pattern.

Authors:  Gianmarco Tuzzato; Roberta Laranga; Federico Ostetto; Elisa Bubbico; Giulio Vara; Giuseppe Bianchi
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

4.  Contrast-enhanced ultrasound-guided musculoskeletal biopsies: our experience and technique.

Authors:  Steven P Daniels; Lori Mankowski Gettle; Donna G Blankenbaker; Kenneth S Lee; Andrew B Ross
Journal:  Skeletal Radiol       Date:  2020-09-15       Impact factor: 2.199

5.  Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.

Authors:  Liam A McDonnell; Judith V M G Bovée; Bram Heijs; Stephanie Holst-Bernal; Marieke A de Graaff; Inge H Briaire-de Bruijn; Mar Rodriguez-Girondo; Michiel A J van de Sande; Manfred Wuhrer
Journal:  Lab Invest       Date:  2020-04-27       Impact factor: 5.662

6.  Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience.

Authors:  Yoon Jung Oh; Seong Yoon Yi; Ki Hyang Kim; Yong Jin Cho; Seung Hoon Beum; Young Han Lee; Jin-Suck Suh; Hyuk Hur; Kyung Sik Kim; Sung Hoon Kim; Young Deuk Choi; Kyoo-Ho Shin; Hyun Jung Jun; Sung Joo Kim; Jeeyun Lee; Se Hoon Park; Sung Hoon Noh; Sun Young Rha; Hyo Song Kim
Journal:  J Cancer       Date:  2016-06-07       Impact factor: 4.207

7.  Myxoid Liposarcoma: Prognostic Factors and Metastatic Pattern in a Series of 148 Patients Treated at a Single Institution.

Authors:  Francesco Muratori; Leonardo Bettini; Filippo Frenos; Nicola Mondanelli; Daniela Greto; Lorenzo Livi; Alessandro Franchi; Giuliana Roselli; Maurizio Scorianz; Rodolfo Capanna; Domenico Campanacci
Journal:  Int J Surg Oncol       Date:  2018-05-16

8.  Complete Remission of Recurrent Retroperitoneal Liposarcoma after the Administration of Gemcitabine and Docetaxel as First-Line Adjuvant Chemotherapy: A Case Report.

Authors:  Filipe Rocha Da Silva; Alan Vitor Jerônimo Lima; Erick Willian Rocha Pereira Albuquerque; Carlos Augusto Moreira-Silva; Nicole Maués Flexa De Oliveira; Jorge Alberto Langbeck Ohana; Luís Eduardo Werneck Carvalho
Journal:  Case Rep Oncol       Date:  2018-05-31

9.  Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis.

Authors:  Kamil M Amer; Dominick V Congiusta; Jennifer E Thomson; Samer Elsamna; Iftikhar Chaudhry; Anthony Bozzo; Rami Amer; Brianna Siracuse; Michelle Ghert; Kathleen S Beebe
Journal:  J Clin Orthop Trauma       Date:  2020-04-18

Review 10.  Management of myxoid liposarcoma of the extremity.

Authors:  Yehia Tfayli; Ahmad Baydoun; Ahmad Salaheddine Naja; Said Saghieh
Journal:  Oncol Lett       Date:  2021-06-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.